Baseline characteristics among Olmsted County, Minnesota, residents with incident or recurrent VTE unrelated to current or recent hospitalization, 2005-2010
| Baseline characteristic . | DVT or PE . | |
|---|---|---|
| Incident (n = 509) . | Recurrent (n = 170) . | |
| Age, mean (SD), y | 59.4 (18.2) | 62.2 (18.0) |
| Female | 255 (50.1) | 64 (37.6) |
| BMI, mean (SD), kg/m2 | 30.3 (7.5) | 31.0 (8.6) |
| Idiopathic* | 206 (40.5) | 108 (63.5) |
| Nursing home confinement | 15 (3.0) | 11 (6.5) |
| Active cancer | 95 (18.7) | 21 (12.4) |
| Trauma | 7 (1.4) | 1 (0.6) |
| Fracture | 27 (5.3) | 3 (1.8) |
| Leg paresis | 20 (3.9) | 3 (1.8) |
| Immobilization† | 150 (29.5) | 31 (18.2) |
| Autoimmune disease‡ | 19 (5.9) | 3 (1.9) |
| Superficial vein thrombosis | 66 (13.0) | 29 (17.1) |
| Heparin or warfarin§ | 11 (2.2) | 13 (9.2) |
| Among women | ||
| Oral contraceptives | 50 (19.6) | 3 (4.7) |
| Infertility drugs | 1 (0.4) | 0 (0.0) |
| Pregnancy | 8 (3.1) | 0 (0.0) |
| Postpartum | 0 (0.0) | 0 (0.0) |
| Estrogen | 8 (3.1) | 1 (1.6) |
| Progestin | 8 (3.1) | 0 (0.0) |
| Tamoxifen | 5 (2.0) | 1 (1.6) |
| Raloxifene | 4 (1.6) | 1 (1.6) |
| Baseline characteristic . | DVT or PE . | |
|---|---|---|
| Incident (n = 509) . | Recurrent (n = 170) . | |
| Age, mean (SD), y | 59.4 (18.2) | 62.2 (18.0) |
| Female | 255 (50.1) | 64 (37.6) |
| BMI, mean (SD), kg/m2 | 30.3 (7.5) | 31.0 (8.6) |
| Idiopathic* | 206 (40.5) | 108 (63.5) |
| Nursing home confinement | 15 (3.0) | 11 (6.5) |
| Active cancer | 95 (18.7) | 21 (12.4) |
| Trauma | 7 (1.4) | 1 (0.6) |
| Fracture | 27 (5.3) | 3 (1.8) |
| Leg paresis | 20 (3.9) | 3 (1.8) |
| Immobilization† | 150 (29.5) | 31 (18.2) |
| Autoimmune disease‡ | 19 (5.9) | 3 (1.9) |
| Superficial vein thrombosis | 66 (13.0) | 29 (17.1) |
| Heparin or warfarin§ | 11 (2.2) | 13 (9.2) |
| Among women | ||
| Oral contraceptives | 50 (19.6) | 3 (4.7) |
| Infertility drugs | 1 (0.4) | 0 (0.0) |
| Pregnancy | 8 (3.1) | 0 (0.0) |
| Postpartum | 0 (0.0) | 0 (0.0) |
| Estrogen | 8 (3.1) | 1 (1.6) |
| Progestin | 8 (3.1) | 0 (0.0) |
| Tamoxifen | 5 (2.0) | 1 (1.6) |
| Raloxifene | 4 (1.6) | 1 (1.6) |
Values are reported as n (%) of patients unless otherwise indicated.
DVT or PE occurring in the absence of hospitalization for surgery or for acute medical illness, nursing home confinement, trauma, fracture, active cancer, neurological disease with leg paresis, immobilization, pregnancy or the postpartum period, oral contraceptive use, or hormone therapy (estrogen and/or progestin) in the 92 days preceding the VTE event date.
Medical record evidence of immobilization in the 92 days preceding the VTE event date.
Autoimmune disease consists of systematic lupus erythematosus, mixed connective tissue disease, progressive systemic sclerosis, dermatomyositis, or rheumatoid arthritis at any time prior to a VTE event.
UFH, LMWH, or warfarin in the 92 days preceding the VTE event date.